Dame Amanda Gay Fisher is a British cell biologist and Director of the Medical Research Council (MRC) London Institute of Medical Sciences[3] at the Hammersmith Hospital campus of Imperial College London, where she is also a Professor leading the Institute of Clinical Sciences.[7][8][9][10][11][12][13] She has made contributions to multiple areas of cell biology, including determining the function of several genes in HIV and describing the importance of a gene's location within the cell nucleus.
As a postdoctoral researcher, she produced the first functional copies of HIV, providing researchers with access to enough biologically active material to study the function of the virus's genes. She later became interested in epigenetics and nuclear reprogramming, particularly in white blood cells known as lymphocytes and embryonic stem cells. As of 2016[update] her research focuses on how gene expression patterns are inherited when cells divide, using lymphocytes as a model system.[14]
Fisher's research[16] has used lymphocytes as a model to analyse how gene expression patterns are transmitted through cell division. Fisher also explored the molecular basis of lineage choice. She studies the transcriptional and epigenetic mechanisms that underlie cellular differentiation and experimental reprogramming.[17]
Her research activities also include pluripotency and reprogramming, polycomb repressor complexes in stem cells, cohesion function in gene expression and genome organisation with Ikaros family transcription factors (TFs). She uses current technologies to address events involved in maintaining embryonic stem (ES) cell pluripotency versus differentiation towards mesoderm, endoderm and ectoderm, as well as the mechanisms of T cell and B cell lineage choice and differentiation.[17]
HIV/AIDS
Fisher's discoveries in HIV were extensive and critical for future research of the virus's characteristics. She produced the first functional copies of HIV, allowing her and other scientists to access biologically active material for future research of the virus's genes.[14] She determined the roles of several of the genes in HIV. These findings have been significant in studying and understanding different characteristics of HIV and Human T-lymphotropic virus (HTLV).[18]
At the NIH, Fisher developed approaches that allowed the successful introduction of exogenous DNA onto human blood cells. Two methods, protoplast fusion and electroporation, proved successful and allowed Fisher to test whether molecular clones isolated from HIV-infected cultures could generate infectious retrovirus upon transfection.[citation needed]
Fisher showed in 1985 that molecular clones of HIV, contained within approximately 18kb of contiguous proviral DNA, were biologically active and generated cytopathic virus when introduced into primary human T-cells.[citation needed] This established that products of the viral genome itself, rather than a cofactor or contaminant, were capable of killing human T cells and were therefore potentially capable of mediating the immunosuppressive effect of HIV. It provided the basis for dissecting the molecular function of each of the viral genes and for developing DNA-based diagnostic tests for HIV infection.[citation needed]
Over the following four years, Fisher showed that the transactivator gene tat was essential for virus replication, that truncation of the 3' open reading frame (ORF) disrupts virus cytopathogenicity, and that sor (now called vif) is required for efficient cell to cell transmission of HIV virus. With clinical collaboration from the Walter Reed National Military Medical Center Fisher showed that patient antisera displayed type-specific neutralising properties and that multiple HIV isolates derived from a single patient were biologically diverse and contained replication-competent as well as replication-incompetent cytopathic variants.[citation needed]
Human T cell development
Fisher moved from the US to the UK in 1987 to study human T cell development. She established the first human thymus organ cultures in 1990, based on studies pioneered by Owen and Jenkinson in the mouse.[citation needed] This refinement allowed cell-fate to be mapped in vitro and provided a system in which potential factors that shape the human T cell repertoire could be experimentally tested.[citation needed] She spent a further 3 years training in mouse genetics, transgenic and knockout technologies at the Institut de génétique et de biologie moléculaire et cellulaire (IGBMC) Strasbourg, before being invited by the Medical Research Council to establish a research team with her partner Matthias Merkenschlager at what was then the Clinical Sciences Centre (CSC).[citation needed] Fisher joined the CSC in 1993, and subsequently became its director in 2008.[citation needed] At the CSC her work has focused on understanding gene regulation during cell commitment. In January 2017, the CSC was renamed the MRC London Institute of Medical Sciences (MRC LMS).[citation needed]
Epigenetics and chromatin
In 1997, Fisher's group published an important paper[10] on the DNA-binding factor Ikaros, that at the time was presumed to be a transcriptional activator.[citation needed] Fisher's group showed that Ikaros proteins unexpectedly localised to percentric heterochromatin in cycling lymphocytes in association with transcriptionally silent genes.[citation needed] This provided some of the first evidence that where a gene is located inside the nucleus may be relevant for its expression. The development of three dimensional (3D) immuno-FISH techniques by Fisher's team, in which the protein structure and the nuclear architecture of a sample remains preserved, was critical for revealing the spatial distribution of chromosomes and the genes within the nucleus.[citation needed] In the last 15 years, analogous approaches have been widely used to interrogate the relationship between gene function and nuclear organisation. For example, studies showed that Ikaros- target genes in T and B cells were recruited to pericentric heterochromatin domains only when gene silencing was inherited by daughter cells.[citation needed] This study, together with others, established that the nuclear location, physical compaction and local chromatin environment of many genes was important for maintaining heritable silencing. Subsequent studies to characterise the differences between transient and heritable/permanent silencing revealed that several silent genes that were assumed to replicate late during synthesis phase (S-phase) of the cell cycle (based on Fluorescence in situ hybridisation (FISH) detection of doublet signals), actually replicated much earlier (based on quantitative increases in DNA content). This discovery in 2003, led Fisher and Merkenschlager to hypothesis that – rather than altering the time of DNA replication – heritable gene silencing could retard chromatid separation and resolution. From this viewpoint they began a series of studies that have subsequently shown the involvement of cohesin complexes in gene regulation and in 2002, Fisher was awarded the EMBO Gold Medal in recognition of her early work on HIV, and the role of nuclear organisation in gene regulation.
Since 2003, Fisher has been studying gene regulation in embryonic stem cells (ES), as a model for understanding pluripotency, lineage commitment and lineage restriction.[citation needed] In 2006, she showed that the promoters of many lineage-specifying genes in ES cells were simultaneously enriched for modified histones thought to mark either active genes (such as acetylation of H3K9, di- and tri-methylation of H3K4), or repressed domains ( such as tri-methylation of H3K27).[citation needed] This discovery ran contrary to the prevailing dogma of the time: that chromatin markers of actively transcribed and inactive domains were mutually exclusive.[citation needed] The study was published in 2006, contemporaneously with similar reports from several US-based groups. suggesting that important developmental regulator genes might be poised for transcription in ES cells, yet repressed by the activity of Polycomb Repressor Complexes (PRCs).[citation needed]
In 2003 she was elected a Fellow of the Academy of Medical Sciences (FMedSci) for excellence in her contributions to medicine and society.[8] Fisher organises and participates in a range of public engagement projects and events, and in recognition of this work she received an 'Outstanding Women in Science Award for communication in Science, Engineering Technology (SET) award in March 2010. Fisher was awarded the Helmholtz Association of German Research Centres International Fellow award in 2015.[17]
^Anon (2001). "EMBO Member: Amanda Fisher". people.embo.org. Heidelberg: European Molecular Biology Organization. Archived from the original on 29 November 2016. Retrieved 28 November 2016.
^Fisher, A. G.; Brown, G (1980). "A rapid method for determining whether monoclonal antibodies react with the same or different antigens on the cell surface". Journal of Immunological Methods. 39 (4): 377–85. doi:10.1016/0022-1759(80)90238-0. PMID7007517.
^Amanda Fisher publications indexed by the Scopus bibliographic database. (subscription required)
^Azuara, V; Perry, P; Sauer, S; Spivakov, M; Jørgensen, H. F.; John, R. M.; Gouti, M; Casanova, M; Warnes, G; Merkenschlager, M; Fisher, A. G. (2006). "Chromatin signatures of pluripotent cell lines". Nature Cell Biology. 8 (5): 532–8. doi:10.1038/ncb1403. PMID16570078. S2CID52868579.
^ abcAnon (2014). "Professor Amanda Fisher FMedSci FRS". London: royalsociety.org. Archived from the original on 4 March 2016. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
^ abcAnon (2016). "Lymphocyte Development". csc.mrc.ac.uk. MRC Clinical Sciences Centre. Archived from the original on 28 April 2016. Retrieved 25 November 2016.
